First clinical experience with a novel, mobile cone-beam CT system for treatment quality assurance in brachytherapy

Andre Karius1,2 · Vratislav Strnad1,2 · Michael Lotter1,2 · Stephan Kreppner1,2 · Christoph Bert1,2

Received: 26 October 2021 / Accepted: 16 February 2022 / Published online: 12 March 2022 © The Author(s) 2022

Abstract

Background and purpose On-site cone-beam computed tomography (CBCT) has gained in importance in adaptive brachytherapy during recent years. Besides treatment planning, there is increased need particularly for image-guidance during interventional procedures and for image-guided treatment quality assurance (QA). For this purpose, an innovative CBCT device was rolled out at our hospital as the first site worldwide. We present the first clinical images and experiences.

Materials and methods The novel CBCT system is constructed of a 121 cm diameter ring gantry, and features a 43.2 × 43.2 cm² flat-panel detector, wireless remote-control via tablet-PC, and battery-powered maneuverability. Within the first months of clinical operation, we performed CBCT-based treatment QA for a total of 26 patients (8 with breast, 16 with cervix, and 2 with vaginal cancer). CBCT scans were analyzed regarding potential movements of implanted applicators in-situ during the brachytherapy course.

Results With the presented device, treatment QA was feasible for the majority of patients. The CBCT scans of breast patients showed sufficient contrast between implanted catheters and tissue. For gynecologic patients, a distinct visualization of applicators was achieved in general. However, reasonable differentiations of organic soft tissues were not feasible.

Conclusion The CBCT system allowed basic treatment QA measures for breast and gynecologic patients. For image-guidance during interventional brachytherapy procedures, the current image quality is not adequate. Substantial performance enhancements are required for intraoperative image-guidance.

Keywords Image-guidance · Adaptive brachytherapy · Gynecologic brachytherapy · On-site computed tomography imaging · Mobile imaging

Introduction

Computed tomography (CT) is a well-established imaging modality and integral part of the imaging workflow in several medical specialties [1–9]. In recent years, particularly cone-beam CT (CBCT) has found increasing applications for interventional [1] and intraoperative [2, 3] purposes.

One factor for this is that corresponding mobile devices as C-arms [1–4] or O-arms [5] allow working flexible at the patient, even in imaging position.

Potential for CBCT in brachytherapy is undoubted. Due to the modality’s good high-contrast capability, resolution, and geometric accuracy, CBCT allows in general distinct visualizations of inserted applicators [6]. As examples, Peters et al. [7] performed CBCT-based adaptive planning of seed implantations into the prostate. Al-Halabi et al. [8] reported respective brachytherapy planning for cervical cancer. Besides treatment planning, there is increased need also for improvements in treatment quality assurance (QA), both during the surgical procedure and throughout the therapy course. This is crucial for therapy success, since interfractio- nal applicator position changes might have significant effects on the dose delivered to target volumes and organs at risk (OARs) [10–14]. Image-guided real-time checks of applicator positions appear essential to account for patient-specific clinical requirements and to ensure accurate appli-
CBCT scanners for interventional environments usually feature mobile designs [15–18]. Concurrently, they show significant image quality limitations compared to conventional CT, especially regarding image artifacts [15–18]. The clinical use of respective devices may require more effort than three-dimensional (3D) C-arms [19], due to larger space requirements. In this respect, a compact device design is considered important for the smooth integration in interventional workflows. Furthermore, to enable patient examinations in the lithotomy position required for intraoperative brachytherapy, a large gantry clearance is crucial. One way to combine these requirements is the usage of vast flat-panel detectors (FPDs). These enable examinations of large anatomical regions of interest (ROIs) with one single gantry rotation and non-moving patient table. In addition to CBCT, radiography and fluoroscopy can be performed with FPDs in general. The combination of these imaging modalities particularly provides the possibility of 2D–3D image registration. This has shown to enable rapid assessments of surgical outcomes such as implant stability [20, 21].

On-site CBCT enables the cross-sectional visualization of the patient anatomy with applicators in situ directly at the brachytherapy ward. This allows both treatment planning as well as intraoperative and interfractional treatment QA measures. For this purpose, we rolled out the innovative CBCT system ImagingRing m (IRm) as the first site worldwide. The clinical introduction started in February 2021 and focused on patients with breast cancer and gynecologic malignancies. We present the first clinical images and experiences.

**Materials and methods**

**ImagingRing m**

The ImagingRing m (IRm) features CBCT, radiography, and fluoroscopy as imaging modalities. It is constructed of a 121 cm ring gantry, on which X-ray source and 43.2 × 43.2 cm² flat-panel detector (FPD) are mounted (Fig. 1). Source and detector can rotate independently along the gantry, thus, allowing for non-isocentric imaging. The FPD is by default operated with a frame rate of 12 Hz and 300 µm pixel size. For detailed technical specifications of the system, please refer to its physical characterization published previously [22].

Within a so-called volume–definition workflow (VDW), four independently, dynamically collimating jaws allow non-isocentric imaging and user-controlled beam-shaping. In this VDW, anterior–posterior and lateral topograms are taken first. Based on these images, the 3D field of view (FOV) of a CBCT scan can then be specified prior its acquisition. Fully opened, the jaws provide for each projection a maximum isocentric planar FOV of 25.4 × 25.4 cm². For beam quality adjustments, six different prefilters (air; 1.5 mm Al; 0.2 mm, 0.5 mm, and 1.5 mm Cu; 0.3 mm Cu BowTie) can be inserted into the beam path. Four built-in cameras enable patient monitoring during examinations.

The IRm is operated via WLAN remote-control by means of a portable so-called Human Machine Interface (HMI) that is established on a Windows® (Microsoft, Redmond, Washington, USA)-based tablet-PC. Motorized wheels at the bottom of each leg (Fig. 1) as well as gearboxes enable lateral and longitudinal movements, free rotations, and ±30° gantry tilt. All movements can be per-
formed battery-powered for up to 30 min. This facilitates changing the premises in which the system is used.

The IRm distinguishes itself from previous CBCT systems [1–5] particularly by the battery-powered mobility, tablet-PC operation, dynamic collimation, non-isocentric imaging, as well as large gantry and FPD. Prior to the device’s clinical roll-out, we conducted a profound technical characterization of its imaging performance using standard QA phantoms. We have reported our results recently [22] (please refer to this publication for detailed information). Due to the good high-contrast visualization achieved in these studies, the IRm was considered suitable for the detection of brachytherapy applicators.

**Workflow for breast/gynecologic brachytherapy**

At our institution, interstitial brachytherapy as sole therapy modality for breast cancer is performed as high-dose-rate (HDR) Accelerated Partial Breast Irradiation (APBI) [23, 24]. Cervix and vaginal cancers are treated with intracavitary and interstitial techniques. Treatment is performed either in the HDR or pulsed-dose-rate (PDR) regime, depending on specific entity and case.

For gynecologic tumors, brachytherapy starts with the intrauterine, intravaginal, and/or interstitial insertion of appropriate applicators, which are chosen adapted to the prevailing tumor characteristic. This is performed under general anesthesia and guided by transrectal ultrasound. For breast brachytherapy, the implantation of flexible plastic catheters into the breast tissue is performed under radiography control. Following these steps, the irradiation is planned based on CT scans with applicators in situ. The full treatment usually lasts one week for PDR gynecologic and HDR breast patients, and a few days to weeks for HDR gynecologic patients (depending on the case).

About halfway through the treatment period, we acquire a control-CBCT with the IRm (see scheme in Table 1). Patients at high risk of applicator displacement due to repositioning are excluded. For breast patients, we perform this CBCT check to detect potential catheter arrangement variations in situ and to assess the necessity for treatment adaptations. These proceedings follow the methodologies described in detail by Kallis et al. [25].

For the QA of gynecologic brachytherapy, we analyze the CBCT scans immediately after acquisition in search for potential applicator position changes. Senior physician and medical physicist assess the relative distances between needles and applicators in all three main planes as well as multiplanar reconstructions. Both the distances between the individual applicator and needle tips as well as the in-plane distances between applicators and needles at the symphysis level are measured. The measured distances are then compared to the intended distances, which are documented on the (day 0) planning-CT. Moreover, we visually inspect the exact positions of needle tips and the centered location of the probe within the uterus. For patients who may be subject to swaps in afterloader transfer tubes, X-ray markers are inserted into the applicators to verify the proper applicator–transfer tube assignment. All these factors ensure that the intended dose distribution can be delivered technically correct to the tissue. If discrepancies are found in any of the above, treatment adaption by re-planning or applicator adjustment is foreseen.

**Patient and imaging parameters**

Within the first 3 months of the IRm’s clinical operation, we treated 8 breast, 16 cervix, and 2 vaginal cancer patients with the described workflow. All gynecologic patients were treated with PDR brachytherapy. Patient characteristics are listed in Table 2.

The IRm did not feature scan protocols for breast and pelvis imaging sufficient for our clinical requirements nor an automatic exposure control. Therefore, the in-house development of protocols and the manual adaption of protocol parameters (prefiltering, current–time product, etc.) to varying patient characteristics was necessary. These proceedings were based on our experience and particularly on the results of the extensive physical characterization of the device [22].

All examinations were performed using the VDW. Patients were always lying on a carbon fiber table (Fig. 1). Breast patients were scanned head-first supine in breath-hold with an acquisition time of 16–18 seconds. Gynecologic patients were examined feet-first supine with flat-lying/non-bent knees (Fig. 1) and filled bladder. The median acquisition time was 40 seconds (range 19–70 seconds). Starting with the eleventh gynecologic patient (named PG11, Table 2), an abdominal belt was tightly applied and butylscopolaminium bromide was administered 15 minutes before each scan. This aimed to reduce image quality deteriorations which may result from respiration or bowel peristalsis.

---

**Table 1** Time scheme for performing control-CBCT acquisitions

| Tumor entity   | Treatment modality | Slot for control-CBCT |
|----------------|--------------------|-----------------------|
| Breast cancer  | HDR, 9 × 3.8 Gy    | After 4th fraction    |
|                | HDR, 2 × 7 Gy      | Prior to 2nd fraction |
|                | PDR, 70 × 0.5 Gy   | After 35th fraction ±4 h |
|                | HDR, 6 × 5 Gy      | After 3rd fraction    |
| Vaginal cancer | PDR, 70 × 0.5 Gy   | After 35th fraction ±4 h |

CBCT cone-beam computed tomography, HDR high-dose-rate, PDR pulsed-dose-rate
Table 2  Characteristics of the examined patients. Furthermore, the contrast–noise ratio (CNR) measured for each patient between catheter and surrounding tissue (for breast patients) and exemplary between uterus and bladder (for gynecological patients) are provided

| ID  | Age | BMI | No. of catheters | CNR  | ID  | Age | BMI | Cancer | Applicators | CNR  |
|-----|-----|-----|------------------|------|-----|-----|-----|--------|-------------|------|
| PB1 | 48  | 24  | 19               | 7.7  | PG1 | 52  | 29  | Cervix | Fletcher    | 2.4  |
| PB2 | 70  | 29  | 18               | 5.9  | PG2 | 36  | 23  | Cervix | Fletcher    | 0.2  |
| PB3 | 63  | 41  | 20               |      | PG3 | 44  | 24  | Cervix | Fletcher + 6 needles | 4.8  |
| PB4 | 83  | 24  | 22               | 9.2  | PG4 | 40  | 21  | Cervix | Fletcher + 3 needles | 2.5  |
| PB5 | 55  | 34  | 19               |      | PG5 | 62  | 31  | Cervix | Fletcher    | 0.2  |
| PB6 | 61  | 31  | 13               | 8.4  | PG6 | 78  | 20  | Cervix | Fletcher + 3 needles | 2.1  |
| PB7 | 64  | 27  | 18               | 6.1  | PG7 | 62  | 23  | Vagina | Papillon template + 4 needles | 3.2  |
| PB8 | 63  | 25  | 20               | 7.1  | PG8 | 86  | 20  | Vagina | Prostate template + 7 needles | 0.5  |
|     |     |     |                  |      | PG9 | 82  | 23  | Cervix | Syed template + 6 needles | 0.7  |
|     |     |     |                  |      | PG10| 80  | 23  | Cervix | 9 Heymann applicators | 2.3  |
|     |     |     |                  |      | PG11| 41  | 22  | Cervix | Fletcher    | 3.9  |
|     |     |     |                  |      | PG12| 84  | 36  | Cervix | Fletcher + 6 needles | 0.5  |
|     |     |     |                  |      | PG13| 55  | 23  | Cervix | Fletcher    | 1.4  |
|     |     |     |                  |      | PG14| 25  | 24  | Cervix | Fletcher + 2 needles | 1.2  |
|     |     |     |                  |      | PG15| 48  | 23  | Cervix | Syed template + 4 needles | 0.9  |
|     |     |     |                  |      | PG16| 39  | 23  | Cervix | Fletcher + 2 needles | 3.2  |
|     |     |     |                  |      | PG17| 61  | 20  | Cervix | Syed template + 10 needles | 3.5  |
|     |     |     |                  |      | PG18| 64  | 35  | Cervix | Fletcher    | 1.6  |

Median 63 28 – 7.7 – 58 23 – – – 2.1
Range 48–83 24–41 – 5.9–9.2 – 25–86 20–36 – – 0.2–4.8

BMI body mass index in kg/m², ID identification

*aNo scan, due to technical problems

*bNo compliance with breathing commands, blurred catheter paths

Assessment of structure differentiability

To provide a quantitative measure for the delimitability of individual tissues as target volumes and OARs, we calculated the contrast–noise ratio (CNR) for each scan. This is a decisive metric for the distinct differentiation of structures:

\[
\text{CNR}_{1,2} = \frac{|\text{ROI}_1 - \text{ROI}_2|}{\sqrt{\frac{1}{\sigma_1^2 + \sigma_2^2}}}
\]

\(\text{ROI}_1\) and \(\text{ROI}_2\) denote the mean CT numbers, \(\sigma_1\) and \(\sigma_2\) the CT-number standard deviations of the considered ROIs, respectively. For breast patients, CNR was measured between catheters (\(\text{ROI}_1\)) and surrounding tissue (\(\text{ROI}_2\)) (Fig. 2). For gynecologic patients, CNR was exemplarily assessed between uterus (\(\text{ROI}_1\)) and bladder (\(\text{ROI}_2\)). These regions were selected, since they usually show a good CT contrast. The ROIs were in each case placed in the immediate vicinity of bladder catheter and applicator tip, respectively (Fig. 2).

Results

For six breast patients, a control-CBCT to planning-CT registration and reconstruction of catheter tracks was performed according to Kallis et al. [25]. In none of these cases, treatment adaption became necessary. All patients underwent tumor resection prior to brachytherapy and therefore had surgical clips marking the tumor bed. These were clearly identifiable on the CBCT scans (Fig. 3). A reasonable median CNR of 7.7 (range 5.9–9.2; Table 2) between catheters and surrounding tissue was obtained. Hence, the image quality was sufficient for treatment QA in each case. This was achieved at reasonable dose levels, with a median X-ray exposure of 5.1 mGy (weighted cone-beam dose index \(\text{CBDI}_w\), range 2.7–8.3 mGy). One breast patient did not comply with the given breathing commands.
which led to severe motion artifacts. Another patient could not be examined due to technical problems.

The CBCT scans of gynecologic patients allowed in general distinct visualizations of implanted applicators, due to their high contrast to the tissue (Fig. 4). The courses of vaginal and intrauterine applicators were well identifiable for the majority of patients. In each of these cases, applicator position control could be performed. In none of these cases, relevant positional changes, shifts, or slippage were identified. The deviations of the applicator and needle distances measured on the control-CBCT to the ones documented on the planning-CT are provided in Table 3 for each patient. The applicator–transfer tube assignment was feasible by following the courses of the inserted X-ray markers (Fig. 4, PG3). However, the exact position verification of implanted needles was not always possible. This was specifically the case when needles and particularly needle tips were in close proximity to sigma or rectum filled with intestinal gas. Here, streaking and shadow artifacts originating from these air–tissue transitions substantially impaired the image quality (Fig. 4). Under these circumstances, the CBCT scans were unsuitable for a complete treatment QA. This was the case for 5 of the 18 examined patients (Table 3).

Although the IRm was principally suitable for validating applicator positions, the device showed distinct weaknesses in the imaging of gynecologic patients. As mentioned, severe artifacts occurred at air–tissue transitions. In addition, directional noise originating from pelvic bones and hardening artifacts in the applicators’ vicinity further impaired image quality (Fig. 4). A clear delineation of organic structures (especially of cervix, uterus, and intestine)
Fig. 4 Representative control-CBCTs of gynecologic patients. The applicators were identifiable in each case. For PG3, the applicator-transfer tube assignment was checked by following the inserted X-ray markers (black arrow). However, particularly in sagittal/coronal planes, no clear soft tissue differentiation was feasible in general. Significant artifacts at air–tissue transitions (e.g., PG6, PG10, PG15), directional noise (e.g., PG8, PG11, PG16), and hardening artifacts (e.g., PG3, PG8, PG17) appeared. Images were selected so that each applicator type was represented at least twice, or once if it was used once only. Level: 40 HU, Width: 500 HU

Discussion

By means of the IRm, we created a time-efficient workflow for the QA of breast and gynecologic brachytherapy. The versatile battery-powered mobility allowed fast maneuvers of the device. The reconstructed images were quickly available, which enabled direct and fast assessments regarding decisions on potential therapy adaptions. In this respect, a mobile CBCT system on-ward strongly facilitates the brachytherapy workflow, since neither patients nor staff have to be sent to more distant CT scanners. This leads particularly to the technical feasibility of performing a treatment QA also for gynecologic patients, which was previously not practicable due to the high effort involved (e.g. transport to distant CT scanners). Such a high effort in particular also precludes the acquisition of magnetic resonance imaging (MRI) scans at off-site locations. On-site MRI for interventional purposes, which would be most desirable due to the superior soft tissue delineability [27–29], is logistically still not implementable at many brachytherapy sites at all.

For none of the examined patients, the necessity for therapy adaption was diagnosed. Despite this positive experience, performing a treatment QA is considered important for therapy success. For breast patients, Kallis et al. [25] showed that treatment adaptions are indicated in 4% of all cases. For gynecologic brachytherapy, other authors already found substantial variations of the dose delivered to target volumes and OARs throughout the treatment course as well as the identification of vessels and ureters was not possible in general, due to insufficient contrast differences (Fig. 4). This assessment was quantitatively confirmed by the low CNR (median 2.1, range 0.2–4.8; Table 2) measured exemplarily between uterus and bladder. Thus, despite a high median CBDI of the examinations of 26 mGy (range 9–50 mGy), individual soft tissues could not be differentiated sufficiently. Note, that the examined patients had a median BMI of 23 (range 20–36; Table 2) and thus represented in general normal weighted patients [26].

Regarding the workflow, the gantry’s large diameter allowed working free and flexible at the patient, e.g., for connecting afterloader transfer tubes. The vast FPD combined with the VDW facilitated the acquisition of FOVs sufficiently dimensioned for applicator arrangement control, as well as exact FOV adjustments even for non-isocentric patient positions. Due to its motorized mobility, the system can be maneuvered time-efficiently into imaging position regardless of the exact patient table position within the room. The total time from patient positioning (including repositioning of immobile patients from bedside) to the examination end was <5 minutes for all patients. In each case, the CBCT scans were available fully reconstructed in <50 seconds after acquisition completion. Hence, the fast assessment of all images could always be performed directly on the HMI.
Table 3  Mean and maximum distance deviations between applicator/needle positions, measured between planning-CT and control-CBCT for gynecologic patients. The distances between the individual applicator/needle tips and the in-plane distances at the symphysis level were considered. We also indicated if the treatment quality assurance (QA) was significantly affected by image artifacts.

| ID   | Mean deviation at symphysis level [mm] | Maximum deviation at symphysis level [mm] | Mean deviation between tips [mm] | Maximum deviation between tips [mm] | Needles/applicators significantly affected |
|------|---------------------------------------|------------------------------------------|---------------------------------|------------------------------------|-------------------------------------------|
| PG1  | 0.7                                   | 1.2                                      | 0.9                             | 1.9                                | –                                         |
| PG2  | 0.9                                   | 1.6                                      | 2.0                             | 2.7                                | –                                         |
| PG3  | 0.5                                   | 1.5                                      | 0.5                             | 0.8                                | –                                         |
| PG4  | 0.4                                   | 0.8                                      | 1.2                             | 2.3                                | 2                                         |
| PG5  | 0.2                                   | 0.6                                      | 2.0                             | 2.9                                | –                                         |
| PG6  | 0.4                                   | 0.7                                      | 1.3                             | 2.8                                | 1                                         |
| PG7  | 0.4                                   | 0.7                                      | 0.3                             | 0.6                                | 2                                         |
| PG8  | 0.7                                   | 1.5                                      | 1.1                             | 2.9                                | –                                         |
| PG9  | 0.7                                   | 1.7                                      | 0.8                             | 1.7                                | 5                                         |
| PG10 | Not measured, Heymann-Packing         | Not measured, Heymann-Packing            | 1.4                             | 2.4                                | –                                         |
| PG11 | 0.5                                   | 0.7                                      | 1.5                             | 2.5                                | –                                         |
| PG12 | 0.9                                   | 2.0                                      | 2.0                             | 2.7                                | –                                         |
| PG13 | 0.6                                   | 1.1                                      | 1.2                             | 2.4                                | –                                         |
| PG14 | 0.5                                   | 0.8                                      | 0.7                             | 1.3                                | 1                                         |
| PG15 | 0.7                                   | 1.2                                      | 0.9                             | 1.9                                | –                                         |
| PG16 | 0.5                                   | 1.0                                      | 0.8                             | 2.8                                | –                                         |
| PG17 | 0.6                                   | 1.5                                      | 1.4                             | 2.9                                | –                                         |
| PG18 | 1.1                                   | 1.3                                      | 1.5                             | 2.3                                | –                                         |

ID = identification, PGx = Gynecologic patient number x

These were related to both inter- and intrafractional anatomical variations (e.g., organ and patient motion), which may lead to altered applicator positions with significant dosimetric impact [10–14]. It is one very important precondition of adaptive brachytherapy to detect such applicator arrangement changes and to adapt the treatment instantaneously to the altered conditions. In this respect, the implementation of automated procedures for treatment plan verification and immediate re-planning (in case of plan invalidity) is most desirable. Hence, this is the subject of ongoing research [10, 30, 31]. In summary, it is important for the precise therapy of patients to perform a treatment QA. CBCT represents a functional and smooth modality for this purpose.

For breast patients, the IRm’s image quality fulfilled clinical requirements at reasonable dose levels. The obtained CNR between catheters and tissue of at median 7.7 was approximately in the range of planning-CTs (median CNR of about 9, measured as described in the “Assessment of structure differentiability” section). Thus, the CBCT scans enabled distinct catheter reconstructions. Treatment QA for breast patients was therefore feasible by using the IRm scans without major drawbacks compared to conventional CT images. However, the current scan times of the IRm of 16–18 seconds are a disadvantage compared to conventional CT (acquisition time in our clinic: <6 seconds). This was also evident from the fact that one examined patient was not able to hold her breath. In particular, based on our experience, not all patients are able to follow correspondingly long breathing commands immediately after surgery. However, this would be required for the acquisition of planning-CTs. To avoid potential motion or breathing artifacts, it is therefore desired to reduce the IRm’s acquisition time. Currently, this associated with enhanced artifacts and decreased circularity of catheters due to partial undersampling. The scan time reduction with undiminished image quality is therefore subject of ongoing work.

The CBCT scans of gynecologic patients were acquired with a median CBDIw of 26 mGy. This exceeds the dose of comparable devices (CBDIw about 20 mGy) [32] and also conventional CT systems (CTDIvol ≤ 15 mGy) [33, 34]. Despite this increased radiation exposure, distinct differentiation of pelvic organs and tissues were not achievable with the IRm. Target structures and OARs could only be inadequately separated. This was quantitatively confirmed by the CNRs calculated exemplarily between uterus and bladder. With a median CNR of only 2.1, the scans did generally not fulfill Rose’s criterion (Rose’s criterion states that a structure must show a CNR of at least 3 to 5 to be detectable) [35]. This was clear evidence for insufficient low-contrast differences. Please note again that the examined patients represented with a median BMI of 23 in general normal weighted patients, as reported in the “Results” section [26]. The inadequate CNR is therefore not directly attributable to
extreme patient characteristics (such as it might be the case for very obese patients) accompanied by strong object scatter. Rather, it indicates a lack of CT-number contrast in the device’s imaging performance. For comparison, planning-CTs yield a respective median CNR of about 6 (again measured as described above). Furthermore, as mentioned, the IRm showed severe artifacts in the imaging of gynecologic patients.

Based on these observations, we conclude that the routine use of the IRm for the purpose of differentiating pelvic soft tissues is currently not justifiable. In particular, the IRm can currently also not support the intraoperative, image-guided insertion of applicators. This is because (due to the lack of organ differentiability) no reliable prediction can be made in which direction and how far applicators and needles can be inserted without risking injuries of corresponding OARs. In this respect, the imaging performance of the IRm is inferior to conventional CT. However, as reported, the device can be used for the verification of the implant stability in-situ and showed to be in principle applicable for the treatment QA of gynecological patients. Although for some patients (Table 3) image artifacts substantially impaired the precise detection of individual needle tips, the IRm enables imaging for treatment verification directly on the ward. This is a procedure that was previously very impractical in our hospital due to the high effort involved, as described above. We think that the advantage of such an on-site treatment verification outweighs the disadvantage of a suboptimal image quality and can have a large benefit for individual patients.

From our perspective, intraoperative CBCT-guided applicator insertion might represent an important step for adaptive gynecologic brachytherapy at many brachytherapy wards. However, to support this by the IRm, significant improvements of its imaging performance are imperative. This relates in particular to improvements in image contrast and soft tissue delineation. Nonetheless, with CBCT it appears feasible to detect the position of applicators precisely, especially around the fundus uteri or deep in the pelvis (in regions for which transrectal sonography is not or only limited applicable). For this, CBCT imaging is appropriate and beneficial. The principle of mobile, non-isocentric imaging also enables patient examinations directly in the surgical theater. This offers a possibility to improve the accuracy of implantations and consequently of treatment quality. A large gantry, as provided by the IRm, further enables imaging in the lithotomy position. This procedure was previously only possible to a limited extent with other gantry-based CBCT-CT/systems. Hence, we think that mobile CBCT imaging with the IRm has in principle high potential for image-guided adaptive brachytherapy of gynecologic malignancies. However, as mentioned, improvements of the device’s imaging performance are imperative.

Conclusion

By means of a mobile device for on-site CBCT imaging, we implemented a time-efficient workflow for the QA of breast and gynecologic brachytherapy. However, significant performance enhancements of the IRm are strictly required for treatment planning imaging and, most desirable, intraoperative image-guidance.

Acknowledgements The present work was performed by Andre Karius in (partial) fulfillment of the requirements for obtaining the degree “Dr. rer. biol. hum.” at the Friedrich-Alexander Universität Erlangen-Nürnberg.

Author Contribution Andre Karius and Christoph Bert carried out extensive physical measures, including protocol optimizations and quality assurance (QA), essential for the device’s clinical roll-out. Together with Vratislav Strnad, Michael Lotter, and Stephan Kreppner, the clinical introduction of the system was completed and adaptations in our brachytherapy workflow were implemented. The latter three were also instrumental for both assessing the acquired images and the following validation of needs for therapy adaptations. All authors performed the overall performance assessment of the device and of the first clinical experiences as well as revised the manuscript critically and approved its final version to be published.

Funding Open Access funding enabled and organized by Projekt DEAL.

Conflict of interest A. Karius, V. Strnad, M. Lotter, S. Kreppner and C. Bert declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Orth RC, Wallace MJ, Kuo MD (2008) C-arm cone-beam CT: general principles and technical considerations for use in interventional radiology. J Vasc Interv Radiol 19(6):814–820
2. Golshan M, Mahdavi SS, Samei G et al (2020) Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours. Brachytherapy 19(5):589–598. https://doi.org/10.1016/j.brachy.2020.06.003
3. Song DY, Jain AK, Zhang Z et al (2011) Dynamic intraoperative dosimetry for prostate brachytherapy using a nonisocentric C-arm. Brachytherapy 10(2):98–106. https://doi.org/10.1016/j.brachy.2010.06.005
4. Sheth NM, De Silva T, Uneri A et al (2019) A mobile isocentric C-arm for intraoperative cone-beam CT: technical assessment of dose and 3D imaging performance. Med Phys 47(3):958–974. https://doi.org/10.1002/mp.13983
5. Shu W, Zhu H, Liu R et al (2019) Posterior percutaneous endoscopic cervical foraminotomy and discectomy for degenerative cervical radiculopathy using intraoperative O-arm imaging. Wideochir Inne Tech Maloinwazyjne 14(4):551–559. https://doi.org/10.5114/wiitm.2019.88660

6. Song WY, Tanderup K, Pieters BR (eds) (2017) Emerging technologies in Brachytherapy, 1st edn. CRC press. pp 233–242

7. Peters M, Smit Duijzenkunst DA, Westendorp H et al (2017) Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for 125I prostate brachytherapy. Brachytherapy 16(2):282–290. https://doi.org/10.1016/j.brachy.2016.11.018

8. Al-Halabi H, Portellance L, Duclos M et al (2010) Cone beam CT-based three-dimensional planning in high-dose-rate brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 77(4):1092–1097. https://doi.org/10.1016/j.ijrobp.2009.06.036

9. Feng A, Shao Y, Wang H et al (2021) A novel lung-avoidance planning strategy based on 4DCT ventilation imaging and CT density characteristics for stage III non-small-cell lung cancer patients. Strahlenther Onkol 197:1084–1092. https://doi.org/10.1007/s00066-021-01821-1

10. Gladwish A, Ravi A, Barbera L et al (2018) Characterizing the impact of adaptive planning on image-guided perineal interstitial brachytherapy for gynecologic malignancies. Brachytherapy 17(2):352–359. https://doi.org/10.1016/j.brachy.2017.11.005

11. Simha V, Patel FZ, Sharma SC et al (2014) Evaluation of intrafractional movements of the organs at risk in image-based brachytherapy of cervical cancer. Brachytherapy 13(6):562–567. https://doi.org/10.1016/j.brachy.2014.05.016

12. Mazeron R, Champoudry J, Gilmore J et al (2015) Intrafractional organs movement in three-dimensional image-guided adaptive pulsed-dose-rate cervical cancer brachytherapy: assessment and dosimetric impact. Brachytherapy 14(2):260–266. https://doi.org/10.1016/j.brachy.2014.11.014

13. Nescavi N, Tanderup K, Hellebust TP et al (2013) A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy. Radiother Oncol 107(1):20–25. https://doi.org/10.1016/j.radonc.2013.01.012

14. Tanderup K, Nescavi N, Pötter R et al (2013) Uncertainties in image guided adaptive cervix cancer brachytherapy: impact on planning and prescription. Radiother Oncol 107(1):1–5. https://doi.org/10.1016/j.radonc.2013.02.014

15. Chernavsky NE, Morcos M, Wu P, Viswanathan AN, Siewerdsen JH (2019) Technical assessment of a mobile CT scanner for image-guided brachytherapy. J Appl Clin Med Phys 20:187–200. https://doi.org/10.1002/acm2.12738

16. Nagarajappaa AK, Dwivedi N, Tiwari R (2015) Artifacts: The downturn of CBCT image. J Int Soc Prev Community Dent 5(6):440–445. https://doi.org/10.4103/2221-0762.170523

17. Daly MJ, Siewerdsen JH, Moseley DJ, Jaffray DA, Irish JC (2006) Intraoperative cone-beam CT for guidance of head and neck surgery: assessment of dose and image quality using a C-arm prototype. Med Phys 33(10):3767–3780. https://doi.org/10.1118/1.2349687

18. Scarfe WC, Farman AG (2008) What is cone-beam CT and how does it work? Dent Clin North Am 52(4):707–730. https://doi.org/10.1016/j.cden.2008.05.005

19. Keil H, Vetter SY, Grützner PA, Franke J (2021) Intraoperative computed tomography in orthopaedic trauma surgery. Z Orthop Unfall. https://doi.org/10.1055/a-1373-6492

20. Uneri A, DeSilva T, Stayman JW, Kleinzig G, Vogt S, Kharma AJ, Gokaslan ZL, Wolinsky JP, Siewerdsen JH (2015) Known-compoment 3D-2D registration for quality assurance of spine surgery pedicle screw placement. Phys Med Biol 60(20):8007–8024. https://doi.org/10.1088/0031-9155/60/20/8007

21. Zvonarev PS, Farrell TJ, Hunter R, Wierzbicki M, Hayward JE, Sur RK (2013) 2D/3D registration algorithm for lung brachytherapy. Med Phys 40:21913. https://doi.org/10.1118/1.4786663

22. Karius A, Karolczak M, Sstrand V, Bert C (2021) Technical evaluation of the cone-beam computed tomography imaging performance of a novel, mobile, gantry-based X-ray system for brachytherapy. J Appl Clin Med Phys. https://doi.org/10.1002/acm2.13501

23. Ott OJ, Sstrand V, Hildebrandt G et al (2016) GE-C-ESTRO multi-institution phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Onc 120(1):119–123. https://doi.org/10.1016/j.radonc.2016.06.019

24. Sstrand V, Ott OJ, Hildebrandt G et al (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):223–238. https://doi.org/10.1016/s0140-6736(15)00471-7

25. Kallis K, Ziegler M, Lotter M et al (2019) Is adaptive treatment planning in multi-catheter interstitial breast brachytherapy necessary? Radiother Oncol 141:304–311. https://doi.org/10.1016/j.radonc.2019.08.015

26. WHO (2000) Obesity: preventing and managing the global epidemic. WHO technical report series 894. WHO, Genf

27. Jääskeläinen E, Kärkkäinen H, Palmgren JE et al (2021) MRI-guided brachytherapy for locally advanced cervical cancer: program initiation, learning curve and dose delivery results in Kuopio University Hospital. Brachytherapy 20(4):738–747. https://doi.org/10.1016/j.brachy.2021.02.006

28. Wu PY, Wong TPW, Yip YYC et al (2019) MRI-guided adaptive brachytherapy for locally advanced cervix cancer: treatment outcomes from a single institution in Hong Kong. Brachytherapy 18(2):171–179. https://doi.org/10.1016/j.brachy.2018.11.007

29. Vojtíšek R, Hošek P, Sukovská E et al (2022) Treatment outcomes of MRI-guided adaptive brachytherapy in patients with locally advanced cervical cancer: institutional experiences. Strahlenther Onkol. https://doi.org/10.1007/s00066-021-01887-x

30. Van den Enle RJP, Rijkmans EC, Kerkhof EM et al (2018) Benefit of adaptive CT-based treatment planning in high-dose-rate endorectal brachytherapy for rectal cancer. Brachytherapy 17(1):78–85. https://doi.org/10.1016/j.brachy.2017.08.011

31. Belliveau JG, Thind K, Banerjee R et al (2019) The impact of inter-fraction changes for perineal template-based interstitial gynecologic brachytherapy implants. J Contemp Brachytherapy 11(2):122–127. https://doi.org/10.5114/jcb.2019.84420

32. Buckley JG, Wilkinson D, Malaroda A et al (2018) Investigation of the radiation dose from cone-beam CT for image-guided radiotherapy: a comparison of methodologies. J Appl Clin Med Phys 19(1):174–183. https://doi.org/10.1002/acm2.12239

33. Abuzaid MM, Elshami W, Tekin HO et al (2020) Computed tomography radiation doses for common computed tomography examinations: a nationwide dose survey in United Arab Emirates. Insights Imaging. https://doi.org/10.1186/s13244-020-00891-6

34. Herts BR, Baker ME, Obuchowski N et al (2013) Dose reduction for abdominopelvic MDCT after change to graduated weight-based protocol for selecting quality reference tube current, peak Kilovoltage, and slice collimation. Med Phys Inform 2006(6):1298–1303. https://doi.org/10.2214/AJR.12.9387

35. Cherry SR, Sorensen JA, Phelps ME (2021) Physics in nuclear medicine. Elsevier, p 244